Supriya Lifescience Limited has submitted to the Exchange, the Unaudited financial results for the quarter ended June 30, 2025.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience reported Q1 FY26 revenue from operations of ₹1,450.74 million, down about 9.7% from ₹1,606.26 million in Q1 FY25. Total income fell to ₹1,477.48 million from ₹1,628.50 million year-on-year. Profit after tax declined to ₹347.90 million from ₹446.44 million, a drop of roughly 22%, translating to EPS of ₹4.32 versus ₹5.54 in the same quarter last year. Sequentially too, both revenue and profit fell sharply from Q4 FY25 levels (₹1,841.09 million revenue, ₹503.82 million PAT). The auditor (Kakaria and Associates LLP) issued an unqualified limited review report with no qualifications, emphasis of matter, or going concern flag.
The double-digit YoY decline in both revenue and profit, along with visible margin compression, is likely to be viewed negatively by the market in the near term. Investors should watch for commentary from management on demand softness, pricing pressure, or order timing issues in the upcoming earnings call.